President Donald Trump signed an executive order Monday establishing a dedicated Women’s Health Division within the National Institutes of Health alongside a White House task force focused on women’s wellness. Accompanied by First Lady Melania Trump, who spearheaded the policy push, the president directed federal agencies to expand biomedical research and streamline the translation of clinical findings into medical practices for female patients across all life stages. According to the directive, “Despite considerable advances in biomedical science, many diseases and conditions that disproportionately or uniquely affect women have not received the level of research, clinical attention, and treatment that other diseases and conditions have received”.
The decree gives the Department of Health and Human Services and the NIH 90 days to institute the new division, which will operate alongside the agency’s long-standing Office of Research on Women’s Health. NIH Director Jay Bhattacharya noted that the entity is designed to close scientific gaps regarding biological sex differences, accelerating therapeutic applications for conditions such as endometriosis, maternal health issues, heart disease, autoimmune disorders, and menopause. Concurrently, the newly formed White House Women’s Health Task Force, co-chaired by HHS Secretary Robert F. Kennedy Jr. and White House Chief of Staff Susie Wiles, will synchronize federal policy across health agencies to modernize care standards and support regulatory updates.
During a ceremony in the Rose Garden, First Lady Melania Trump outlined key objectives for the initiative, emphasizing the integration of artificial intelligence to expedite medical discoveries, the development of targeted therapeutics, and making life-saving treatments more affordable. Addressing attendees, she stated, “Our mission must serve women at every stage of life”. The administration’s platform also seeks to reduce public stigma surrounding midlife female medical conditions and lower financial barriers to necessary treatments.
The executive mandate incorporates administrative actions by the Food and Drug Administration, including efforts to re-evaluate safety warnings on hormone replacement therapies and approve new medications for postmenopausal symptom management. Additionally, federal health officials unveiled specialized research collaboratives aimed at tracking diagnostic follow-up timelines for breast cancer and evaluating maternal-infant outcomes tied to fertility treatments. Observers noted that the order focuses heavily on midlife health, menopause, and chronic conditions while omitting specific language concerning reproductive rights and contraception research.
Editorial credit: Rawpixel.com via Shutterstock.com